BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Casula M, Catapano AL, Magni P. Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet). Nutrients 2022;14:606. [DOI: 10.3390/nu14030606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs 2023. [PMID: 36941490 DOI: 10.1007/s40265-023-01841-4] [Reference Citation Analysis]
2 Magni P, Baragetti A, Poli A. Special Issue: Nutraceutical Approaches to Cardiovascular and Metabolic Diseases: Evidence and Opportunities. Nutrients 2022;14. [PMID: 36558557 DOI: 10.3390/nu14245399] [Reference Citation Analysis]
3 Djuricic I, Calder PC. Polyunsaturated fatty acids and metabolic health: novel insights. Curr Opin Clin Nutr Metab Care 2022. [PMID: 35943130 DOI: 10.1097/MCO.0000000000000865] [Reference Citation Analysis]
4 Wang C, Yu P, Hu L, Liang M, Mao Y, Zeng Q, Wang X, Huang K, Yan J, Xie L, Zhang F, Zhu F. Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.921803] [Reference Citation Analysis]
5 Blais JE, Huang X, Zhao JV. Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials.. [DOI: 10.1101/2022.06.20.22276676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]